Go online to PeerView.com/KTS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in managing patients with thyroid cancer discusses the scientific background and rationale for molecular testing and targeted treatment of RET fusion/mutation–positive thyroid cancers, new data on novel targeted approaches, the importance of multidisciplinary collaboration, and how to effectively communicate with patients to promote shared decision-making and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the heterogeneity of thyroid cancers and the rationale for integrating molecular testing into practice to inform treatment decisions, Discuss the evolving evidence on molecular testing for RET fusions/mutations in thyroid cancer and best practices for its use to guide therapy selection, Evaluate clinical trial data on novel, targeted therapies for patients with thyroid cancers that harbor genomic abnormalities, such as RET fusions/mutations, Implement collaborative strategies among endocrinologists, pathologists, and oncologists to ensure widespread genomic testing to identify appropriate patients for RET-targeted therapy in the context of clinical practice or clinical trials, Communicate effectively with patients with thyroid cancer to address their concerns and questions about their disease, treatment options, and prognosis and promote shared decision-making.